目的:评估澳大利亚临床实践指南开发小组的性别组成;探索影响小组组成的指南开发相关因素。
方法:2010-2020年澳大利亚发布的临床指南调查,观察了2016年NHMRC指南标准,在NHMRC临床实践指南门户网站或通过搜索指南国际网络指南库确定(2021年6月),Trip医疗数据库,和PubMed。从性别标题(指南文件)或代词(在线传记)推断指南制定贡献者的性别。
方法:指南小组成员的总体比例-正式考虑证据并制定建议的指南贡献者(即,指南小组主席和成员)-谁是女性。
结果:在406个符合条件的指南中,335列出了对他们的发展做出贡献的人的名字(82%)。在7472个指定的贡献者中(包括511个指南小组主席[6.8%]和5039个指南小组成员[67.4%]),男性3514人(47.0%),3345名女性(44.8%),612例(8.2%)无法确定性别。共有215位指引小组主席为女性(42.1%),280名男性(54.8%);2566名指导小组成员为男性(50.9%),2071名女性(41.1%)。在179个指南中,女性指南小组成员的比例小于40%(53%),在71个指南中,女性指南小组成员的比例大于60%(21%)。除了两年(2017年,2018年)外,女性小组成员的中位数指南比例均小于50%。
结论:在澳大利亚,妇女在卫生领导角色中的代表性并不反映她们在卫生保健队伍中的参与程度。特别是,临床指南制定机构应制定透明的政策,以增加妇女在指南制定小组中的参与。
To assess the composition by gender of Australian clinical practice guideline development panels; to explore guideline development-related factors that influence the composition of panels.
Survey of clinical
guidelines published in Australia during 2010-2020 that observed the 2016 NHMRC Standards for
Guidelines, identified (June 2021) in the NHMRC Clinical Practice
Guideline Portal or by searching the
Guideline International Network
guidelines library, the Trip medical database, and PubMed. The gender of contributors to guideline development was inferred from gendered titles (guideline documents) or pronouns (online biographies).
The overall proportion of guideline panel members - the guideline contributors who formally considered evidence and formulated recommendations (ie, guideline panel chairs and members) - who were women.
Of 406 eligible guidelines, 335 listed the names of people who contributed to their development (82%). Of 7472 named contributors (including 511 guideline panel chairs [6.8%] and 5039 guideline panel members [67.4%]), 3514 were men (47.0%), 3345 were women (44.8%), and gender could not be determined for 612 (8.2%). A total of 215 guideline panel chairs were women (42.1%), 280 were men (54.8%); 2566 guideline panel members were men (50.9%), 2071 were women (41.1%). The proportion of female
guideline panel members was smaller than 40% for 179
guidelines (53%) and larger than 60% for 71
guidelines (21%). The median guideline proportion of female panel members was smaller than 50% for all but two years (2017, 2018).
The representation of women in health leadership roles in Australia does not reflect their level of participation in the health care workforce. In particular, clinical guideline development bodies should develop transparent policies for increasing the participation of women in guideline development panels.